Russian approval for Glenmark’s Montlezir

| Updated on September 30, 2019 Published on October 01, 2019

Glenmark Pharmaceuticals, a research led, integrated global pharmaceutical company, today announced that it has received approval from the Ministry of Healthcare, Russia, to market Montlezir (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film coated tablets as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age. Montlezir is expected to be available in the Russian market in Q3 FY2019-20. Shares of Glenmark closed 2.55 per cent lower at ₹324.80 on the BSE.

Published on October 01, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.